SCHEMBL3460501

SCHEMBL3460501

CSc1nc(N)nc(N[C@@H](CCCNC(C)=O)C(=O)Nc2cccc(C(F)(F)F)c2)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ PKM P14618 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ TRPV4 Q9HBA0 1/20 0.39
▸ MAPT P10636 4/20 0.37
▸ RXFP1 Q9HBX9 2/20 0.37
▸ TP53 P04637 2/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ POLB P06746 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10180845 0.94 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL12946922 0.94 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL966006 0.93 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL964362 0.92 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL964825 0.91 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL3459376 0.91 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL12946908 0.90 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL12915851 0.90 CA1 (0.46) SMN1; SMN2KMT2AMEN1PKMHPGD
SCHEMBL10327185 0.90 TRPV4 (0.41) SMN1; SMN2KMT2AMEN1LMNATHRB
SCHEMBL3459084 0.89 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMEN1PKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678168-B1 P70S6 KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2012-07-11 — — EP claimed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US claimed
EP-1678168-B1 P70S6 KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2012-07-11 — — EP disclosed
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EXELIXIS, INC. (US) 2011-01-27 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EXELIXIS, INC. 2007-09-06 — — US disclosed
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EXELIXIS, INC. 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EEF2K, RPS6KA3, MTOR SMN1; SMN2 2850/4885KMT2A 3420/4885MEN1 4049/4885
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EEF2K, RPS6KA3, MTOR SMN1; SMN2 2850/4885KMT2A 3420/4885MEN1 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback